Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

Rhea-AI Summary

Syndax Pharmaceuticals will release its second quarter 2021 financial results on August 9 after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. The company is focused on developing cancer therapies, including SNDX-5613, axatilimab, and entinostat. Investors can access the live webcast and slides on the Syndax website.

Positive

• Scheduled financial results release for Q2 2021 on August 9.
• Focus on innovative cancer therapies with promising pipeline.

Negative

• None.

WALTHAM, Mass., Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2021 financial results on Monday, August 9, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, August 9, to discuss the Company's financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Conference ID: 2871946
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast:  https://edge.media-server.com/mmc/p/n7kmwwkz

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.

About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-second-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-august-9-2021-301344944.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax announce its Q2 2021 financial results?

Syndax will announce its Q2 2021 financial results on August 9, 2021.

What time is the conference call for Syndax's Q2 2021 financial results?

The conference call is scheduled for 4:30 p.m. ET on August 9, 2021.

How can I access Syndax's financial results webcast?

The webcast can be accessed through the Events & Presentations page on Syndax's website.

What therapies is Syndax Pharmaceuticals developing?

Syndax is developing cancer therapies including SNDX-5613, axatilimab, and entinostat.